Persistent Systems is currently trading at Rs. 4763.00, up by 43.25 points or 0.92% from its previous closing of Rs. 4719.75 on the BSE.

The scrip opened at Rs. 4601.30 and has touched a high and low of Rs. 4771.35 and Rs. 4601.30 respectively. So far 19715 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6597.00 on 23-Dec-2025 and a 52 week low of Rs. 4163.80 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 4800.00 and Rs. 4498.10 respectively. The current market cap of the company is Rs. 74622.06 crore.

The promoters holding in the company stood at 30.29%, while Institutions and Non-Institutions held 52.61% and 17.10% respectively.

Persistent Systems is working with NVIDIA to accelerate the development and deployment of AI-powered solutions for the Healthcare and Life Sciences (HLS) industry. The collaboration will help HLS organizations advance computational drug discovery and improve research outcomes using Generative AI and advanced analytics. 

HLS organizations are under increasing pressure to drive innovation while operating in highly complex, regulated and data-intensive environments. Combining Persistent’s deep domain and engineering expertise with the full-stack NVIDIA AI platform, Life Sciences enterprises can move from AI experimentation to real-world production deployments in mission-critical environments.

Persistent will leverage NVIDIA AI Enterprise for specialized Life Sciences R&D use cases, including preclinical research. By enabling high-fidelity molecular simulation and virtual screening at scale, the collaboration applies AI to model and reason real-world biological and chemical behavior before it is realized in real-world wet laboratory environments. 

As part of this collaboration, Persistent will build and deploy production-grade Agentic AI applications for computational drug discovery using NVIDIA NeMo. Specifically, Persistent has created a Generative Molecules and Virtual Screening (GenMoIVS) solution, powered by the NVIDIA BioNeMo platform and NVIDIA NeMo Agent Toolkit. GenMoIVS will deliver AI-driven molecular simulations that model the physical and chemical properties of molecules using large domain-specific models and create intelligent agents to streamline real-time drug discovery workflows.

Persistent Systems is a global company specializing in software product and technology services.